Respect autonomy: involve clients in setting goals and let them make choices
And finally, we have semaglutide, the active ingredient in Wegovy and Ozempic
To view or add a comment, sign in A new milestone for diabetes care! Oral semaglutide just earned FDA approval for reducing cardiovascular risks in high-risk type 2 diabetes patients a major step forward in cardiometabolic health. Read More: #FDAApproval #DiabetesCare #Semaglutide #PharmaNews #HealthcareInnovation #OneAlphaMed FDA Clears Oral Semaglutide for Heart Protection in Diabetes! A landmark approval! The FDA has officially approved oral semaglutide to reduce cardiovascular events in high-risk type 2 diabetes patients reinforcing its dual impact on metabolic control and heart health
While side effect profiles are expected to mirror those of injectable semaglutide (such as nausea, vomiting, and constipation), the incidence and severity remain to be fully characterized through larger-scale trials
By mimicking the effects of a natural hormone that regulates appetite, Semaglutide helps reduce food cravings and promotes a feeling of fullness
Patients evaluating GoodLife Meds Review should verify: (1) prescriber board certifications via state medical boards, (2) pharmacy 503A licensing and accreditation status, (3) whether baseline labs (metabolic panel, lipid profile, thyroid function) are included, and (4) documented follow-up intervals
